Case series adds clinical evidence for ILE in pet neurotoxicosis

A new multicenter case series suggests intravenous lipid emulsion therapy may do what clinicians have long hoped in dogs and cats with suspected neurotoxicosis: shift toxic compounds into the plasma lipid fraction, with higher lipid-to-aqueous ratios linked to better short-term neurologic improvement. The study, posted as a 2026 preprint and associated with eight European veterinary hospitals, included 34 companion animals, 27 dogs and 7 cats, treated with a standardized ILE protocol. Permethrin and THC were the most commonly detected xenobiotics. Importantly, the authors did not find that a toxin’s published log P value reliably predicted either plasma partitioning or early neurologic outcome. (preprints.org)

Why it matters: For veterinary professionals, the findings add in vivo clinical evidence supporting the “lipid sink” or “lipid shuttle” concept, but they also reinforce that ILE remains a selective, not automatic, tool. The study’s outcome window was only 4 to 6 hours, the sample was small, and prior literature shows mixed benefit and some risk, including reported adverse effects in about 5.8% of dogs and cats in a large retrospective series, while the MSD Veterinary Manual notes some toxicants, including bromethalin and calcium channel blockers, may worsen after ILE. That makes case selection, monitoring, and realistic expectations especially important in ER and critical care settings. (preprints.org)

What to watch: Watch for peer-reviewed publication of the full dataset, and for whether these findings shape more specific recommendations on when ILE should be used, and when it shouldn’t. (research-portal.uu.nl)